Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Cost and Access Head-to-Head

How These Two Drugs Actually Work

Vardenafil and alprostadil treat erectile dysfunction through entirely separate pathways, which is why one can succeed when the other fails. Vardenafil is a phosphodiesterase type 5 (PDE5) inhibitor that blocks the enzyme responsible for breaking down cyclic GMP in penile smooth muscle, allowing nitric-oxide-mediated vasodilation to persist during sexual stimulation [1]. Alprostadil is synthetic prostaglandin E1, delivered either by intracavernosal injection (Caverject, Edex) or intraurethral pellet (MUSE), and it directly relaxes smooth muscle independent of the nitric oxide pathway [2].

This mechanistic difference matters for cost-and-access decisions because it determines which patients each drug serves. Vardenafil requires intact nerve signaling and endothelial nitric oxide release to work. Men with severe neurogenic or vasculogenic ED, post-radical prostatectomy patients, or those with diabetes-related endothelial damage may not generate enough nitric oxide for a PDE5 inhibitor to amplify. In the Linet et al. trial published in the New England Journal of Medicine (N=296), intracavernosal alprostadil produced erections sufficient for intercourse in approximately 70% of men, including those refractory to oral agents [2]. That rescue capability is the clinical reason alprostadil remains on formularies despite its higher cost.

Vardenafil itself demonstrated strong efficacy in diabetic populations. Porst et al. (2003) showed that vardenafil 10 mg and 20 mg significantly improved erectile function scores in men with diabetes and ED (N=452), with 57% and 72% of attempts resulting in successful intercourse at those respective doses [1].

Retail Cost: What You Will Actually Pay

The price gap between these two drugs is the single biggest factor separating them for most patients. Generic vardenafil tablets (10 mg and 20 mg) are available at major U.S. chain pharmacies for $1 to $8 per dose, depending on the pharmacy and whether a discount card is applied. A 30-tablet supply typically runs $30 to $120 out of pocket.

Alprostadil costs substantially more. A single Caverject 20 mcg vial ranges from $30 to $75 at retail, and the MUSE 1 to 000 mcg pellet falls in a similar $35 to $65 range per unit. A man using alprostadil twice weekly would spend roughly $260 to $600 per month versus $8 to $64 per month on generic vardenafil at the same frequency.

Brand-name Levitra has been largely discontinued in the U.S. market, and Staxyn (the orally disintegrating vardenafil formulation) has limited distribution. When Staxyn is available, it costs $40 to $60 per tablet, which narrows the gap with alprostadil. Most prescribers now default to generic vardenafil tablets for cost efficiency.

A useful benchmark: the American Urological Association (AUA) guideline on erectile dysfunction recommends PDE5 inhibitors as first-line therapy partly because of their favorable cost-to-efficacy ratio, reserving intracavernosal injection for second-line use [3]. Cost alone does not drive this recommendation, but it reinforces it.

Insurance Coverage and Prior Authorization

Coverage patterns for ED medications have shifted considerably since generic PDE5 inhibitors entered the market. Many commercial plans now cover generic vardenafil as a Tier 2 or Tier 3 formulary drug, though quantity limits (typically 6 to 12 tablets per month) are standard. Some plans impose step therapy, requiring a trial of generic sildenafil before approving vardenafil.

Alprostadil faces a different set of barriers. Caverject and MUSE frequently require prior authorization, and the prescriber must document PDE5 inhibitor failure or contraindication. Even with approval, copays for specialty-tier drugs can reach $50 to $100 per fill. Medicare Part D plans vary, but many exclude ED medications entirely under a longstanding coverage exclusion that dates to the Medicare Modernization Act of 2003. Some Medicare Advantage plans have added limited ED drug benefits, but this is plan-specific and not guaranteed [4].

For veterans, the VA formulary covers both alprostadil injection and PDE5 inhibitors, though with quantity limits and clinical criteria.

One access advantage alprostadil holds: it carries no nitrate contraindication. Men taking nitroglycerin or isosorbide for coronary artery disease cannot safely use vardenafil or any PDE5 inhibitor due to the risk of severe hypotension. For these patients, alprostadil is not just a second-line option. It is the only pharmacologic ED treatment available, and insurers generally approve it without step therapy when nitrate use is documented [5].

Efficacy Comparison: What the Data Shows

No large, randomized, head-to-head trial has directly compared vardenafil to alprostadil. The comparison must be drawn from separate studies, which limits direct statistical comparison but still provides useful clinical context.

Vardenafil efficacy data. In the Porst et al. study of men with diabetes and ED, vardenafil 20 mg improved the International Index of Erectile Function (IIEF) erectile function domain score by a mean of 7.4 points over placebo (P<0.001, N=452) [1]. Across the broader vardenafil clinical program, successful intercourse rates ranged from 65% to 80% in the general ED population, with lower response rates in men with severe vascular disease or post-prostatectomy nerve injury [6].

Alprostadil efficacy data. The Linet et al. NEJM trial reported that 70% of intracavernosal alprostadil injections (dose range 2.5 to 20 mcg) produced erections rated adequate for intercourse. The response rate remained high even in men who had not responded to oral therapies, which is the population most likely to encounter alprostadil in clinical practice [2]. MUSE (intraurethral delivery) shows lower efficacy than injection, with successful intercourse rates of approximately 40% to 50% in published trials, plus a higher incidence of penile pain [7].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "The real clinical value of alprostadil is that it provides a pathway for men who fail or cannot tolerate oral PDE5 inhibitors. It is not competing with vardenafil in the same patient. It is serving the patient vardenafil could not help."

Convenience, Administration, and Patient Preference

The practical experience of using each drug differs enormously, and this shapes adherence patterns as much as cost does.

Vardenafil is a tablet swallowed with water 30 to 60 minutes before anticipated sexual activity. Food (especially high-fat meals) can delay absorption, but the drug requires no special preparation, no office training, and no needle. This simplicity drives high initial acceptance.

Alprostadil injection (Caverject) requires the patient to draw up the medication and inject it directly into the corpus cavernosum of the penis using a fine-gauge needle. First injections are performed in a clinician's office to titrate the dose and monitor for priapism (prolonged erection lasting more than four hours, a urologic emergency). Once trained, patients self-inject at home.

MUSE involves inserting a small pellet into the urethra via a single-use applicator. It avoids needles but carries a 10% to 30% incidence of urethral burning or pain, and its efficacy is lower than injection [7].

Adherence data reflects these differences. A 2014 review in the Journal of Sexual Medicine found that long-term discontinuation rates for intracavernosal injection therapy range from 40% to 68%, with injection anxiety and partner discomfort cited as leading reasons [8]. PDE5 inhibitor discontinuation rates are lower but still significant, often driven by cost, lack of efficacy, or side effects like headache and flushing.

Side Effects and Safety Considerations

Vardenafil's most common adverse effects include headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%). It carries a QT-prolongation warning and should not be combined with Class IA or Class III antiarrhythmics. The absolute contraindication with nitrates applies to all PDE5 inhibitors, including vardenafil [6].

Alprostadil's side-effect profile is localized. Penile pain at the injection site occurs in 30% to 50% of patients using Caverject, though it tends to diminish with repeated use. Priapism occurs in approximately 1% to 3% of patients and requires emergency intervention if an erection persists beyond four hours. Prolonged use of intracavernosal injections can cause penile fibrosis (scarring) in 5% to 7% of patients, which may worsen erectile function over time [9].

The FDA prescribing information for Caverject recommends no more than three injections per week, with at least 24 hours between injections, to reduce fibrosis risk [2].

Who Should Choose Which Drug

The decision between vardenafil and alprostadil follows a clear clinical algorithm that most urologists and sexual medicine specialists already apply.

Start with vardenafil (or another PDE5 inhibitor) if:

• The patient has no contraindication to PDE5 inhibitors (no nitrate use, no unstable cardiovascular disease)
• Cost and convenience are priorities
• The patient has mild to moderate ED or diabetes-related ED
• The patient has not yet tried an oral PDE5 inhibitor

Move to alprostadil if:

• The patient has failed adequate trials of at least two PDE5 inhibitors at maximum dose
• The patient takes nitrates and PDE5 inhibitors are contraindicated
• The patient has severe neurogenic ED (e.g., post-radical prostatectomy with bilateral nerve injury)
• The patient prefers a faster onset of action (5 to 20 minutes vs. 30 to 60 minutes)

The AUA guideline reinforces this stepwise approach: oral PDE5 inhibitors first, then intracavernosal injection or vacuum erection devices, then penile prosthesis for refractory cases [3].

Telehealth and Online Pharmacy Access

Generic vardenafil is widely available through telehealth platforms that offer online consultations and mail-order delivery. Several direct-to-consumer telehealth companies include vardenafil in their ED medication offerings, often at prices competitive with or below retail pharmacy pricing. A typical online consultation plus a 30-day supply of generic vardenafil ranges from $30 to $90 total.

Alprostadil access through telehealth is more limited. Caverject requires an initial in-office dose titration for safety, and most telehealth platforms do not prescribe injectable ED medications without a documented in-person evaluation. MUSE is occasionally prescribed via telehealth, but its lower efficacy and higher cost make it a less common recommendation. Specialty pharmacies and compounding pharmacies may offer alprostadil formulations at lower cost than brand Caverject, though compounded injectables are not FDA-approved and carry additional quality-control considerations.

According to the Endocrine Society clinical practice guideline on testosterone therapy, men with ED should also be evaluated for hypogonadism, as testosterone replacement can improve PDE5 inhibitor response in men with documented low testosterone [10]. This evaluation is available through both in-person and telehealth providers.

Combination Therapy and Escalation

When a single agent is insufficient, some specialists prescribe combination protocols. Adding low-dose alprostadil injection to an oral PDE5 inhibitor regimen can produce erections in men who respond partially to either drug alone. A 2006 study in the Journal of Urology found that combining a PDE5 inhibitor with intracavernosal alprostadil improved IIEF scores beyond either agent alone in men with severe ED (N=108) [11].

This combination strategy does increase cost, as the patient pays for both medications. It also requires the same in-office injection training and dose titration as standalone Caverject use. Insurance coverage for combination therapy is inconsistent; most plans do not explicitly cover dual ED medications, and prior authorization requirements apply to the alprostadil component.

Dr. Arthur Burnett, professor of urology at Johns Hopkins, has stated: "Combination therapy is not first-line, but for the patient who has partial response to oral therapy and wants to avoid surgery, it represents a reasonable pharmacologic ceiling before considering a penile implant."

The Bottom Line on Cost vs. Clinical Need

Generic vardenafil is the less expensive, more convenient, and more widely accessible option for the majority of men with ED. At $1 to $8 per dose with oral administration, it is the default starting point. Alprostadil costs 5 to 50 times more per dose, requires injection training or urethral insertion, and carries unique risks like priapism and penile fibrosis. Its value is specific: it serves the estimated 30% to 40% of men who do not respond to PDE5 inhibitors, and it is the only pharmacologic option for men on nitrate therapy. The AUA recommends trying at least two PDE5 inhibitors at maximum dose before moving to intracavernosal injection [3]. Men who reach that point should expect monthly costs of $260 to $600 for alprostadil at twice-weekly use, and should confirm prior authorization requirements with their insurer before filling.